Course Director
Carolyn M. Sue, MBBS, PhD, FRACP - University of Sydney, Sydney, Australia

Faculty

Roy N. Alcalay, MD - Columbia University Medical Center, New York, NY, USA

Thomas Foltynie, PhD, MRCP - National Hospital for Neurology, London, United Kingdom

The primary purpose of this program is to address the critical role for pharmaceuticals and devices in genetics in Parkinson's disease.

Lectures will be available for on-demand viewing beginning on June 1, 2022 until August 31, 2022.

Upon completion of this activity, learners will be able to:

1. Describe the phenotype, frequency, and type of mutations of genetic forms of PD

2. Identify current indications, practice, and solutions for genotyping PD patients

3. Discuss potential therapeutic targets and clinical trial designs for genetic forms of PD

This activity is intended for industry professionals who work for pharmaceutical and medical device companies.

Genetics of Parkinson's Disease Virtual Educational Course for Industry Professionals

Sessions available for on demand viewing as of June 1, 2022

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.

2. Compatible with Windows PC and MAC (256 MB of RAM or higher)

3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher

4. Adobe Flash Player 12.0 (or higher).

5. Adobe Reader to print certificate.